Skip to main content
SpringerLink
Log in

Circulating Tumor Cells: Enrichment and Genomic Applications

  • Chapter
  • First Online:
Book cover Genomic Applications in Pathology

Abstract

Recent technical advances have led to an increased interest in the detection and molecular characterisation of circulating tumor cells (CTC). Evaluation of CTC carries great potential as a tool in cancer patient management and prognostication. Numerous clinical trials on early and metastatic cancer are employing CTC to evaluate the efficacy of systemic therapy. There is also an increasing interest in using CTC for detailed molecular and cellular characterization of both well-characterized and novel biomarkers. However, technical difficulties have limited the opportunity to deeply probe these rare events, particularly as they occur in a background of millions of normal cells. Better characterization of CTC should clearly lead to a better understanding of cancer progression, the effects of therapy, and the identification of novel therapeutic targets. CTC evaluation is expected to become more widely used in both clinical and research settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 239.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481(7379):85–9.

    Article  CAS  Google Scholar 

  2. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802.

    Article  PubMed  CAS  Google Scholar 

  3. Balic M, Williams A, Dandachi N, Cote RJ. Micrometastasis: detection methods and clinical importance. Cancer Biomark. 2010;9(1–6):397–419.

    PubMed  Google Scholar 

  4. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110–8.

    Article  PubMed  CAS  Google Scholar 

  5. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol. 2011;77(1):1–11.

    Article  PubMed  Google Scholar 

  6. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.

    Article  PubMed  CAS  Google Scholar 

  8. Liu Z, Fusi A, Klopocki E, Schmittel A, Tinhofer I, Nonnenmacher A, et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med. 2011;9:70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Lustberg M, Jatana KR, Zborowski M, Chalmers JJ. Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res. 2012;195:97–110.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother. 1997;6(2):103–14.

    Article  PubMed  CAS  Google Scholar 

  11. Iinuma H, Okinaga K, Adachi M, Suda K, Sekine T, Sakagawa K, et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer. 2000;89(4):337–44.

    Article  PubMed  CAS  Google Scholar 

  12. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002;49(4):150–8.

    Article  PubMed  CAS  Google Scholar 

  14. Cote RJ, Cordon-Cardo C, Reuter VE, Rosen PP. Immunopathology of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. Am J Pathol. 1990;136(5):1077–84.

    PubMed  CAS  PubMed Central  Google Scholar 

  15. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354(9182):896–900.

    Article  PubMed  CAS  Google Scholar 

  16. Fleischer RL. Cancer filter deja vu. Science. 2007;318(5858):1864.

    Article  PubMed  CAS  Google Scholar 

  17. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156(1):57–63.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204.

    Article  PubMed  CAS  Google Scholar 

  19. Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology. 2004;39(3):792–7.

    Article  PubMed  Google Scholar 

  20. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010;16(20):5011–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007;1162(2):154–61.

    Article  PubMed  CAS  Google Scholar 

  22. Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, et al. A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105(6):847–53.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009;4(3):281–3.

    Article  PubMed  Google Scholar 

  24. Davis JA, Inglis DW, Morton KJ, Lawrence DA, Huang LR, Chou SY, et al. Deterministic hydrodynamics: taking blood apart. Proc Natl Acad Sci U S A. 2006;103(40):14779–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Huang LR, Cox EC, Austin RH, Sturm JC. Continuous particle separation through deterministic lateral displacement. Science. 2004;304(5673):987–90.

    Article  PubMed  CAS  Google Scholar 

  26. Inglis DW, Davis JA, Austin RH, Sturm JC. Critical particle size for fractionation by deterministic lateral displacement. Lab Chip. 2006;6(5):655–8.

    Article  PubMed  CAS  Google Scholar 

  27. Wang XB, Yang J, Huang Y, Vykoukal J, Becker FF, Gascoyne PR. Cell separation by dielectrophoretic field-flow-fractionation. Anal Chem. 2000;72(4):832–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Becker FF, Wang XB, Huang Y, Pethig R, Vykoukal J, Gascoyne PR. Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A. 1995;92(3):860–4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Gascoyne PR, Wang XB, Huang Y, Becker FF. Dielectrophoretic separation of cancer cells from blood. IEEE Trans Ind Appl. 1997;33(3):670–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg. 1995;222(4):415–23. discussion 23–5.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol. 2011;19(1):33–40.

    Article  PubMed  CAS  Google Scholar 

  32. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011;130(2):449–55.

    Article  PubMed  CAS  Google Scholar 

  33. Bartkowiak K, Effenberger KE, Harder S, Andreas A, Buck F, Peter-Katalinic J, et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res. 2010;9(6):3158–68.

    Article  PubMed  CAS  Google Scholar 

  34. Lorico A, Rappa G. Phenotypic heterogeneity of breast cancer stem cells. J Oncol. 2011;2011:135039.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007;9(5):R74.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12.

    Article  PubMed  CAS  Google Scholar 

  37. Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, et al. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res. 2012;10(1):96–107.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Nogami T, Shien T, Tanaka T, Doihara H, Taira N, Takabatake D, et al. The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells. Breast Cancer. 2014;21(1):58–65.

    Google Scholar 

  40. Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013;73(3):1190–200.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Azizi E, Wicha MS. Cancer stem cells—the evidence accumulates. Clin Chem. 2012;59(1):205–7.

    Article  PubMed  Google Scholar 

  42. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  43. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Wang S, Xu ZY, Wang LF, Su W. CD133+ cancer stem cells in lung cancer. Front Biosci (Landmark Ed). 2013;18:447–53.

    Article  CAS  Google Scholar 

  45. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23(43):7267–73.

    Article  PubMed  CAS  Google Scholar 

  46. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005;8(3):227–39.

    Article  PubMed  CAS  Google Scholar 

  47. Cote RJ. Occult metastases: real harm or false alarm? J Thorac Cardiovasc Surg. 2003;126(2):332–3.

    Article  PubMed  Google Scholar 

  48. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12(19):5615–21.

    Article  PubMed  CAS  Google Scholar 

  49. Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, et al. HER2-associated radiation resistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. 2012;18(24):6634–47.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10(2):R25.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26(17):2813–20.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154–9.

    PubMed  CAS  Google Scholar 

  53. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res. 2006;12(19):5606–7.

    Article  PubMed  Google Scholar 

  54. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306(4):385–93.

    Article  PubMed  CAS  Google Scholar 

  55. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44CD24lo cancer stem cell phenotype. Eur J Cancer. 2011;47(10):1527–36.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  56. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288(1):99–106.

    Article  PubMed  CAS  Google Scholar 

  57. Wang N, Shi L, Li H, Hu Y, Du W, Liu W, et al. Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation. Tumour Biol. 2012;33(2):561–9.

    Article  PubMed  CAS  Google Scholar 

  58. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012;139(19):3471–86.

    Article  PubMed  CAS  Google Scholar 

  59. Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer. 2011;129(10):2310–4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Lee K, Nelson CM. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. Int Rev Cell Mol Biol. 2012;294:171–221.

    Article  PubMed  CAS  Google Scholar 

  61. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008;14(9):2593–600.

    Article  PubMed  CAS  Google Scholar 

  63. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  64. Friedlein R, von Kieseritzky F, Braun S, Linde C, Osikowicz W, Hellberg J, et al. Solution-processed, highly-oriented supramolecular architectures of functionalized porphyrins with extended electronic states. Chem Commun (Camb). 2005;21(15):1974–6.

    Article  Google Scholar 

  65. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011;178(3):989–96.

    Article  PubMed  PubMed Central  Google Scholar 

  66. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011;13(1):202.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;137(8):1151–73.

    Article  PubMed  Google Scholar 

  68. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9(4):302–12.

    Article  PubMed  CAS  Google Scholar 

  69. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 2002;20(4):387–92.

    Article  PubMed  CAS  Google Scholar 

  70. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58–68.

    Article  PubMed  Google Scholar 

  71. Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126(3):589–98.

    Article  PubMed  CAS  Google Scholar 

  72. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013;73(1):30–40.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  73. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 2006;6:96.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 2009;277(2):164–73.

    Article  PubMed  CAS  Google Scholar 

  75. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012;12:78.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133(2):346–56.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  77. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer. 2006;94(2):333–7.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.

    Article  PubMed  CAS  Google Scholar 

  79. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  PubMed  CAS  Google Scholar 

  80. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010;5(9):e12517.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Dharmasiri U, Njoroge SK, Witek MA, Adebiyi MG, Kamande JW, Hupert ML, et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem. 2011;83(6):2301–9.

    Article  PubMed  CAS  Google Scholar 

  82. Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol. 2010;17(2):624–33.

    Article  PubMed  Google Scholar 

  83. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130–41.

    Article  PubMed  CAS  Google Scholar 

  84. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003;21(14):2673–8.

    Article  PubMed  CAS  Google Scholar 

  85. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010;56(9):1492–5.

    Article  PubMed  Google Scholar 

  86. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, et al. Global gene expression profiling of circulating tumor cells. Cancer Res. 2005;65(12):4993–7.

    Article  PubMed  CAS  Google Scholar 

  87. Barbazan J, Alonso-Alconada L, Muinelo-Romay L, Vieito M, Abalo A, Alonso-Nocelo M, et al. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One. 2012;7(7):e40476.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  88. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011;17(11):3600–18.

    Article  PubMed  CAS  Google Scholar 

  89. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010;10(5):392–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Marija Balic

  2. Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA

    Richard J. Cote

Authors
  1. Marija Balic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Cote
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Pathology, Oncology and Urology, Johns Hopkins University, Baltimore, Maryland, USA

    George Jabboure Netto

  2. Department of Pathology, Stanford University School of Medicine, Stanford, California, USA

    Iris Schrijver

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Balic, M., Cote, R.J. (2015). Circulating Tumor Cells: Enrichment and Genomic Applications. In: Netto, G., Schrijver, I. (eds) Genomic Applications in Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0727-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0727-4_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0726-7

  • Online ISBN: 978-1-4939-0727-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation